Document Type
Article
Publication Date
7-20-2025
Abstract
The goal of this study was to explore associations between single-nucleotide polymorphisms (SNPs) and umbilical cord blood concentrations of buprenorphine and its metabolites following maternal administration. This is a sub-study of a prospective observational cohort investigation which included pregnant women receiving buprenorphine for opioid use disorder during pregnancy. Following delivery, umbilical cord blood samples were collected and genotyped using a pharmacogenetic panel. The drug and metabolite concentrations were analyzed through liquid chromatography-mass spectrometry, and genetic association analysis was completed using PLINK software. The included neonates (n = 14) had a mean birth weight of 3.00 ± 0.39 kg and were born to mothers receiving a mean buprenorphine dose of 10.29 ± 6.22 mg. Ten concentration groupings (drug, single metabolite, as well as drug/metabolite(s) combinations) produced 18 unique SNP associations. Two significant associations included variations in CYP3A4 and UGT1A1, which play a role in the metabolism of buprenorphine. These preliminary findings suggest potential pharmacogenetic factors influencing fetal drug exposure, warranting larger studies to validate associations and explore clinical implications for neonatal outcomes.
Recommended Citation
Monfared A, Murrell DE, Shah DS, Hoang M, Brown SD, Harirforoosh S. Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood. Toxicol Rep. 2025;15:102093. https://doi.org/10.1016/j.toxrep.2025.102093
Copyright
The authors
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Included in
Maternal and Child Health Commons, Medicinal and Pharmaceutical Chemistry Commons, Substance Abuse and Addiction Commons
Comments
This article was originally published in Toxicology Reports, volume 15, in 2025. https://doi.org/10.1016/j.toxrep.2025.102093